The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas.

Fiche publication


Date publication

janvier 2015

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr FEIN Francine, Pr GHIRINGHELLI François, Dr PAGET-BAILLY Sophie, Dr KIM Stephano, Dr LAKKIS Zaher


Tous les auteurs :
Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C

Résumé

The benefit of preoperative chemotherapy in resectable gastroesophageal adenocarcinomas was not observed in signet ring cell subtype. However, the potential interest of taxane-based preoperative chemotherapy on this subtype is still an unresolved issue. Nineteen patients with localized signet ring cell adenocarcinomas received taxane-based regimens, and 17 patients underwent surgery. Complete resection was achieved in 80 %, and median overall survival was 40.8 months (95 % confidence interval (CI), 20.2-not reached). Even though one patient achieved a complete pathological response, seven patients had an upstaging of their tumors at surgery. The potential benefits of taxane-based chemotherapy seem to be limited to a reduced number of patients.

Référence

J Hematol Oncol. 2015 May 15;8(1):52